# Chiron Real Estate share price today (Chiron Real Estate Inc., XRN)

> Chiron Real Estate Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. XRN · Real Estate · REIT - Healthcare Facilities · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/xrn

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Turning around, from the last 12 quarters
- Price: $30.38 (−1.0% in a year)
- P/E: 8.2× (lower than 92% of the last 1 year)
- Revenue (Jun 2026): $39.7 M (+4.8% on a year ago)
- Profit (Jun 2026), incl. one-off: $63.3 M (one-off item, see below)
- Operating margin: 23.2% (+1.1 points on a year ago)
- ROE: −2%, FY25
- ROIC: 1.8%, against a 6.6% cost of capital: −4.8 points

The main question: the share price moved −1.0% in a year while yearly earnings per share moved −1,572.5%. The difference came from the market paying a higher multiple. ## What is the Chiron Real Estate share price today? Chiron Real Estate Inc.'s share price was $30.38 at the close on 3 November 2026. That is 13.8% below its average price over the last 200 trading days. In the last 52 weeks it traded between $30 and $38, and at that close it sat 5% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 7 weeks running. Over the last 1 year the share price moved −15% while the S&P 500 moved +21%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 18 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Chiron Real Estate pay? Chiron Real Estate Inc. paid $3.03 per share over the last four reported quarters. The most recent declaration was $0.75 for Jun 2026. At today's price of $30.38 that is a yield of 9.97%, based on dividends already paid, not a forecast. ## Which stock lists is Chiron Real Estate on? Chiron Real Estate is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Chiron Real Estate profitable? Chiron Real Estate Inc. earned $63.3 M of net profit in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $12.1 M. That is 159.3% of the quarter's revenue. The same quarter a year earlier lost $800 K. 6 of the last 12 reported quarters were loss-making. For the full year, FY25 profit was −$12.1 M (−1,594.0% on the year before). Read this profit with care: at $63.3 M it is bigger than the quarter's whole revenue of $39.7 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a 23.2% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does Chiron Real Estate make, and is it growing? Chiron Real Estate Inc. reported $39.7 M of revenue in the Jun 2026 quarter, +4.8% on the same quarter a year earlier. That is the 5th quarter in a row with growth on the year before. Over 4 years it has grown 6.3% a year on average. The last full year, FY25, came in at $148 M. The last four reported quarters add to $153 M. FY25 revenue was $148 M, +6.7% on the year before. Recent pace: the last four quarters grew +8.1% on average, against 6.3% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +8.1%, against +5.5% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does Chiron Real Estate keep? Chiron Real Estate Inc.'s operating margin was 23.2% in the Jun 2026 quarter, 1.1 percentage points higher than the same quarter a year ago. Across 5 years it has been between 25.2% and 31.9%. The latest quarter is below every full year in that period. Why: the operating margin move is clear, but the cost details behind it are not in our data, so we show the move without guessing the reason. ## Is Chiron Real Estate's profit turning into cash? Over the last 3 years, 743% of Chiron Real Estate Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $73.6 M of operating cash against −$12.1 M of profit. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets. ## Where does Chiron Real Estate's cash go? Chiron Real Estate Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean. ## What is Chiron Real Estate's P/E ratio, and how does it compare with its own history? Chiron Real Estate Inc.'s P/E is 8.2×, near the low end of its own history: it has been lower only 8% of the time. Its usual P/E (the middle reading) is 96.0×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −1,572.5% while the price moved −1.0%. The price did better than earnings, which pushed the multiple up within its own range. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Chiron Real Estate business getting better or worse? Chiron Real Estate Inc.'s business is turning around. EPS growth has swung from −1379.5% at its low to +1006.2%, improving for 2 quarters in a row, with ROCE steady at 5.0%. This is based on 12 quarters of 4 measures. Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. ## How much does Chiron Real Estate earn on its capital? Chiron Real Estate Inc. earned a ROE of −2% in FY25. Its return on capital used (ROIC) is 4.8 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −8.2% net margin and 0.12× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −8.2% net margin × 0.12× asset turnover × 2.34× leverage (assets divided by equity) ≈ −2.3% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 1.8% − 6.6% = −4.8 percentage points. The 6.6% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Chiron Real Estate have too much debt? Chiron Real Estate Inc. has total debt of $647 M against shareholder equity of $684 M as of Jun 2026, so its debt is 0.95× its equity. Year by year, that ratio went from 0.92 in FY21 to 1.26 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Chiron Real Estate shareholding pattern? 7.6% of Chiron Real Estate Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 7.9 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Chiron Real Estate from balance-sheet trouble? For Chiron Real Estate Inc., the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Chiron Real Estate rank in its industry? 29.6 out of 100, rank 17 of 17 in REIT - Healthcare Facilities, with 69% of the evidence available. Chiron Real Estate Inc. scores 29.6 out of 100 against the 17 companies it is compared with in REIT - Healthcare Facilities, ranking 17. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 13.3 + 8.9 + 4.8 + 2.6 = 29.6. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if ROA turns down or gross NPA rises while the share price lags its sector. ## Which companies is Chiron Real Estate compared with? Chiron Real Estate ranks 17 of 17 REIT - Healthcare Facilities companies on the 4-Factor Sector Score, with 29.6 out of 100. 1. [LTC Properties, Inc.](https://www.sectoralpha.in/us/stocks/ltc) LTC · leader · Most evidence points up · 80% evidence 74.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Income 61% · Profit 61.5% · 81% evidence Capital efficiency 15.9/25 · ROA 4.2% · ROE 8.5% · GNPA n/a · 68% evidence Valuation 12.3/20 · P/BV 1.47× · P/BV÷ROE 0.17 · 70% evidence Relative strength 20.0/20 · Lead over its industry 22.5% · Lead over S&P 500 12.2% · 1 year 27.6% · 100% evidence · 9 of 12 weeks ahead Exact sum: 25.8 + 15.9 + 12.3 + 20 = 74 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Omega Healthcare Investors, Inc.](https://www.sectoralpha.in/us/stocks/ohi) OHI · turning · Most evidence points up · 80% evidence 69.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.2/35 · Income 13.1% · Profit 84.7% · 81% evidence Capital efficiency 18.9/25 · ROA 5.1% · ROE 11.6% · GNPA n/a · 68% evidence Valuation 9.5/20 · P/BV 2.52× · P/BV÷ROE 0.22 · 70% evidence Relative strength 14.2/20 · Lead over its industry 6.8% · Lead over S&P 500 -2.3% · 1 year 9.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.2 + 18.9 + 9.5 + 14.2 = 69.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Strawberry Fields REIT, Inc.](https://www.sectoralpha.in/us/stocks/strw) STRW · quiet · Evidence leans up · 80% evidence 64.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.8/35 · Income 19.4% · Profit 33.3% · 81% evidence Capital efficiency 20.0/25 · ROA 6.3% · ROE 74.9% · GNPA n/a · 68% evidence Valuation 15.0/20 · P/BV 5.66× · P/BV÷ROE 0.08 · 70% evidence Relative strength 6.9/20 · Lead over its industry -0.9% · Lead over S&P 500 -9.3% · 1 year 7.6% · 100% evidence · 0 of 12 weeks ahead Exact sum: 22.8 + 20 + 15 + 6.9 = 64.7 · What this means: Earnings are strong; relative strength in its sector is -0.9% and the one-year return is 7.6%. 4. [Welltower Inc.](https://www.sectoralpha.in/us/stocks/well) WELL · turning · Evidence leans up · 80% evidence 61.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.6/35 · Income 37.6% · Profit 37.3% · 81% evidence Capital efficiency 12.9/25 · ROA 2.2% · ROE 6.8% · GNPA n/a · 68% evidence Valuation 5.0/20 · P/BV 3.36× · P/BV÷ROE 0.49 · 70% evidence Relative strength 18.4/20 · Lead over its industry 17.2% · Lead over S&P 500 7.3% · 1 year 26.8% · 100% evidence · 5 of 12 weeks ahead Exact sum: 25.6 + 12.9 + 5 + 18.4 = 61.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Healthpeak Properties, Inc.](https://www.sectoralpha.in/us/stocks/doc) DOC · quiet · Evidence leans up · 80% evidence 55.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.9/35 · Income 5.5% · Profit 42.5% · 81% evidence Capital efficiency 11.4/25 · ROA 1.1% · ROE 9.2% · GNPA n/a · 68% evidence Valuation 12.7/20 · P/BV 1.55× · P/BV÷ROE 0.17 · 70% evidence Relative strength 14.5/20 · Lead over its industry 8.8% · Lead over S&P 500 -0.4% · 1 year 9.8% · 100% evidence · 2 of 12 weeks ahead Exact sum: 16.9 + 11.4 + 12.7 + 14.5 = 55.5 · What this means: Relative strength against the index is -0.4%, and revenue and profit growth are weak. 6. [National Health Investors, Inc.](https://www.sectoralpha.in/us/stocks/nhi) NHI · basing · Evidence leans up · 80% evidence 53.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.5/35 · Income 23.7% · Profit 16.2% · 81% evidence Capital efficiency 18.0/25 · ROA 4.6% · ROE 10.3% · GNPA n/a · 68% evidence Valuation 9.0/20 · P/BV 2.33× · P/BV÷ROE 0.23 · 70% evidence Relative strength 6.5/20 · Lead over its industry -6.6% · Lead over S&P 500 -14.8% · 1 year -10.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 19.5 + 18 + 9 + 6.5 = 53 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [CareTrust REIT, Inc.](https://www.sectoralpha.in/us/stocks/ctre) CTRE · basing · Evidence leans up · 80% evidence 52.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.6/35 · Income 53.1% · Profit 62.6% · 81% evidence Capital efficiency 15.8/25 · ROA 4.5% · ROE 7.7% · GNPA n/a · 68% evidence Valuation 7.6/20 · P/BV 2.11× · P/BV÷ROE 0.27 · 70% evidence Relative strength 6.8/20 · Lead over its industry -0.9% · Lead over S&P 500 -9.4% · 1 year 1.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 22.6 + 15.8 + 7.6 + 6.8 = 52.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [American Healthcare REIT, Inc.](https://www.sectoralpha.in/us/stocks/ahr) AHR · quiet · Evidence leans down · 69% evidence 48.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.7/35 · Income 16.9% · Profit n/a · 52% evidence Capital efficiency 10.1/25 · ROA 1.9% · ROE 2.8% · GNPA n/a · 68% evidence Valuation 3.8/20 · P/BV 2.69× · P/BV÷ROE 0.96 · 70% evidence Relative strength 16.8/20 · Lead over its industry 12.3% · Lead over S&P 500 2.8% · 1 year 11.1% · 100% evidence · 5 of 12 weeks ahead Exact sum: 17.7 + 10.1 + 3.8 + 16.8 = 48.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Healthcare Realty Trust Incorporated](https://www.sectoralpha.in/us/stocks/hr) HR · basing · Too little evidence to rank firmly · 57% evidence 48.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.6/35 · Income -6.1% · Profit n/a · 52% evidence Capital efficiency 5.5/25 · ROA 0.9% · ROE 0% · GNPA n/a · 68% evidence Valuation 9.8/20 · P/BV 1.64× · P/BV÷ROE n/a · 10% evidence Relative strength 15.3/20 · Lead over its industry 7.6% · Lead over S&P 500 -1.7% · 1 year 6% · 100% evidence · 0 of 12 weeks ahead Exact sum: 17.6 + 5.5 + 9.8 + 15.3 = 48.2 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 10. [Sabra Health Care REIT, Inc.](https://www.sectoralpha.in/us/stocks/sbra) SBRA · quiet · Evidence leans down · 80% evidence 46.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.5/35 · Income 17.7% · Profit -63.9% · 81% evidence Capital efficiency 13.2/25 · ROA 3.2% · ROE 5.8% · GNPA n/a · 68% evidence Valuation 6.8/20 · P/BV 1.79× · P/BV÷ROE 0.31 · 70% evidence Relative strength 14.3/20 · Lead over its industry 7% · Lead over S&P 500 -2.2% · 1 year 7.8% · 100% evidence · 3 of 12 weeks ahead Exact sum: 12.5 + 13.2 + 6.8 + 14.3 = 46.8 · What this means: Relative strength against the index is -2.2%, and revenue and profit growth are weak. 11. [Ventas, Inc.](https://www.sectoralpha.in/us/stocks/vtr) VTR · quiet · Evidence leans down · 80% evidence 46.1 out of 100 Growth Capital Valuation Relative
12. [Medical Properties Trust, Inc.](https://www.sectoralpha.in/us/stocks/mpt) MPT · quiet · Evidence leans down · 69% evidence 43.1 out of 100 Growth Capital Valuation Relative
13. [Universal Health Realty Income Trust](https://www.sectoralpha.in/us/stocks/uht) UHT · basing · Evidence leans down · 80% evidence 42.3 out of 100 Growth Capital Valuation Relative
14. [Sila Realty Trust, Inc.](https://www.sectoralpha.in/us/stocks/sila) SILA · Too little evidence to rank firmly · 56% evidence 38.2 out of 100 Growth Capital Valuation Relative
15. [Community Healthcare Trust Incorporated](https://www.sectoralpha.in/us/stocks/chct) CHCT · basing · Evidence leans down · 69% evidence 36.6 out of 100 Growth Capital Valuation Relative
16. [Diversified Healthcare Trust](https://www.sectoralpha.in/us/stocks/dhc) DHC · quiet · Too little evidence to rank firmly · 57% evidence 35.7 out of 100 Growth Capital Valuation Relative
17. Chiron Real Estate Inc. this page XRN · quiet · Most evidence points down · 69% evidence 29.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.3/35 · Income 7.8% · Profit 100% · 52% evidence Capital efficiency 8.9/25 · ROA 1.8% · ROE 1.3% · GNPA n/a · 68% evidence Valuation 4.8/20 · P/BV 0.73× · P/BV÷ROE 0.56 · 70% evidence Relative strength 2.6/20 · Lead over its industry -9.3% · Lead over S&P 500 -17.1% · 1 year -6.1% · 100% evidence · 0 of 12 weeks ahead Exact sum: 13.3 + 8.9 + 4.8 + 2.6 = 29.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. Financial companies use P/BV÷ROE and asset quality; PEG, industrial OPM and ROCE are excluded. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Jun 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [REIT - Healthcare Facilities](https://www.sectoralpha.in/us/sectors/reit-healthcare-facilities), all 17 compared on one page. ## Which companies are close to Chiron Real Estate in size? Chiron Real Estate is the 16th largest of 17 REIT - Healthcare Facilities companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Diversified Healthcare Trust, Sila Realty Trust, Inc., Medical Properties Trust, Inc., Strawberry Fields REIT, Inc. and Universal Health Realty Income Trust. Just below it: Community Healthcare Trust Incorporated. ### REIT - Healthcare Facilities companies close in size

1. [Diversified Healthcare Trust](https://www.sectoralpha.in/us/stocks/dhc) $1.8 billion
2. [Sila Realty Trust, Inc.](https://www.sectoralpha.in/us/stocks/sila) $1.7 billion
3. [Medical Properties Trust, Inc.](https://www.sectoralpha.in/us/stocks/mpt) $1.2 billion
4. [Strawberry Fields REIT, Inc.](https://www.sectoralpha.in/us/stocks/strw) $701 million
5. [Universal Health Realty Income Trust](https://www.sectoralpha.in/us/stocks/uht) $530 million
6. Chiron Real Estate Inc. $416 million
7. [Community Healthcare Trust Incorporated](https://www.sectoralpha.in/us/stocks/chct) $353 million

[All 17 REIT - Healthcare Facilities companies, largest first](https://www.sectoralpha.in/us/sectors/reit-healthcare-facilities#all-companies)

### Companies close in size in other industries

1. [Chemung Financial Corporation](https://www.sectoralpha.in/us/stocks/chmg) $418 million · Banks - Regional
2. [Intrepid Potash, Inc.](https://www.sectoralpha.in/us/stocks/ipi) $418 million · Agricultural Inputs
3. Chiron Real Estate Inc. $416 million
4. [Materialise NV](https://www.sectoralpha.in/us/stocks/mtls) $415 million · Software - Application
5. [AdvanSix Inc.](https://www.sectoralpha.in/us/stocks/asix) $415 million · Chemicals

## What else do people ask about Chiron Real Estate? ### What were Chiron Real Estate's latest quarterly results? Chiron Real Estate Inc. reported revenue of $39.7 M and net profit of $63.3 M for the Jun 2026 quarter. Earnings per share were $4.78. The operating margin was 23.2%, 1.1 percentage points higher than a year earlier (as of 3 November 2026). ### What is Chiron Real Estate's market cap? Chiron Real Estate Inc.'s market capitalisation is $416 M at a stock price of $30.38. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Chiron Real Estate performing? Chiron Real Estate Inc.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 7 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Chiron Real Estate's stock price go up? This page does not forecast Chiron Real Estate Inc.'s stock price. What it shows instead: the stock price is $30.38. Its P/E of 8.2× is higher than 8% of its own last 1 years. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Is Chiron Real Estate's profit real cash? Yes, over the last 3 years, 743% of Chiron Real Estate Inc.'s reported profit came in as cash from operations. The latest year was lower at -608%, so the trend is worth watching. In FY25, operating cash was $73.6 M against reported profit of −$12.1 M. Most of that cash then goes into a mix of the daily operating cycle and new capacity. These are yearly figures (as of 3 November 2026). ### Where is Chiron Real Estate in its business cycle? Chiron Real Estate Inc.'s FY25 operating margin was 25.2%, against a 5-year range of 25.2% to 31.9%: the low end of its own range, which is often where recoveries start. The latest quarter was 23.2%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Chiron Real Estate story? The main question: the share price moved −1.0% in a year while yearly earnings per share moved −1,572.5%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Chiron Real Estate a stock worth studying right now? What the numbers show: Chiron Real Estate Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.